Recent studies have reported conflicting results regarding the pain-alleviating effects of Rosa Damascena in topical and oral administration forms. Therefore, we evaluated the potential effects of topical application and oral intake of this herbal medicine on adults’ acute pain severity in a meta-analysis. A systematic search was performed on the Cochrane Central Register of Controlled Trials, PubMed, Scopus, Web of Science Core Collection, Embase, Cumulative Index to Nursing and Allied Health Literature, SID, and MagIran from inception to March 20, 2021. We included parallel-group and cross-over randomized controlled trials (RCTs) that compared the effects of any products of Rosa Damascena in oral and topical administration forms to placebo, non-treatment, or conventional treatment. Two independent researchers performed study screening and selection, data extraction, and risk of bias assessment. A random-effect model was used to pool the data. Of the 11 studies that met the inclusion criteria, four and seven administered Rosa damascena through topical application and oral intake, respectively. The oral intake of Rosa damascena reduced pain severity nonsignificantly ]standardized mean difference (SMD): -0.55; 95% confidence interval (CI): -1.27, 0.17; P= 0.132[. However, the topical application of this treatment had no painalleviating effect ]SMD: 0.10; 95% CI: -0.75, 0.96; P= 0.814[. Most studies (n= 6) had fair methodological quality, and one reported mild allergic rhinitis as an adverse effect of the treatment. Further robust RCTs are suggested to compare the effects of oral intake and topical application of Rosa damascena on the severity of different types of acute pain in adults.